News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
byStephen Padilla
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
17 Jul 2023

Danuglipron helps with glucose control, weight loss in T2D
15 Jul 2023
byJairia Dela Cruz
The glucagon-like peptide 1 receptor (GLP-1R) agonist danuglipron appears to be beneficial in the treatment of patients with type 2 diabetes (T2D), yielding reductions in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and body weight, without fasting restrictions, as shown in the results of a phase IIb study.
15 Jul 2023







